Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Diagnoplex S.A. Closes a Financing Round Led by Debiopharm Group™

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
Diagnoplex secures 1.3 million Swiss francs from financing round.

Diagnoplex SA and Debiopharm Diagnostics SA have announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

Other investors include Neomed and Initiative Capital Romandie.

The funds will be used to help Diagnoplex obtain CE marking (European Conformity) for Colox, a non-invasive blood-based test for the early detection of colon cancer.

The company also wishes to prepare a comparative clinical trial with the screening test that should allow for patient reimbursement.

Early detection of colon cancer and subsequent intervention by colonoscopy will have an important impact on the prevention of this cancer that has a high mortality rate. Indeed, it has been demonstrated that survival rates improve up to 90% when colorectal cancer is detected early.

Colorectal cancer is the third most common cancer in men (663 000 cases, 10.0% of the total) and the second in women (571 000 cases, 9.4% of the total) worldwide.

“We are very pleased to announce the renewal commitment of Debiopharm, who led this round. This financing will allow Diagnoplex to continue its development and to progressing in establishing a collaboration for the commercialization of its diagnostic test,” commented Stavros Therianos, Ph.D., Chief Executive Officer and founder of Diagnoplex.

“The early screening of colon cancer is key. It is tomorrow’s personalized medicine. We are proud to contribute to the progress of such an entrepreneurial and innovative company such as Diagnoplex,” said Thierry Mauvernay, Delegate of the Board of Debiopharm Group.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm and EORTC Announce a Collaboration
Collaboration to investigate triptorelin for treatment of salivary gland cancers.
Thursday, January 14, 2016
EMA Grants Orphan Drug Designation to Debio 1143
Company grants EMA Designation to Debio 1143 for treatment of Ovarian Cancer.
Thursday, December 10, 2015
United and Debiopharm Announce the Launch of Pamorelin®
Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines.
Tuesday, December 08, 2015
Debiopharm’s Partner Yakult Announces Elplat® Approbation in Gastric Cancer
Approval for a supplemental new drug application for Elplat® in postoperative adjuvant chemotherapy in Japan.
Saturday, November 28, 2015
JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award
The ‘JCA-Mauvernay Award 2015’ is awarded to Doctors Yutaka Kondo and Junko Takita.
Saturday, October 10, 2015
Debiopharm and Solid Biosciences Announces Collaboration
Debiopharm to start pre-clinical animal studies in Duchenne Muscular Dystrophy with Solid Biosciences.
Thursday, September 10, 2015
Debiopharm Acquires FibroTrap Sample Processing Technology from Spinomix
FibroTrap improves sensitivity and shortens time taken from sample collection to results.
Saturday, June 20, 2015
Debiopharm Announces Phase III Positive Results for Triptorelin 6-month Formulation
Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or reversing progression of clinical signs of puberty and slowing down of accelerated bone maturation in children with CPP.
Friday, May 22, 2015
Debiopharm Initiates Clinical Phase II Study to Evaluate Debio 1450
One year after the initiation of Phase I, Debiopharm has announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID.
Friday, May 01, 2015
Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
Company presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347.
Tuesday, April 21, 2015
Debiopharm Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450
Debio 1450 - A highly potent anti-infective agent selectively active against Staphylococcus species.
Wednesday, October 15, 2014
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
Trelstar® one-, three-, and six-month dosing options now available.
Wednesday, October 08, 2014
Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Debiopharm, Yale University Extend Collaboration
New license and research agreement regarding the discovery of MIF inhibitors.
Wednesday, May 07, 2014
Curis and Debiopharm Report Preclinical Data for Debio 0932
Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
Wednesday, April 09, 2014
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Study Identifies How Brain Connects Memories Across Time
UCLA Neuroscientists have boost ability of aging brain to recapture links between related memories.
3-D Atomic Structure of Cholesterol Transporter
Researchers at UTSW have determined the 3-D atomic structure of a human sterol transporter that helps maintain cholesterol balance.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Can We Break the Link Between Obesity and Diabetes?
Columbia University researchers identify a key molecule involved in the development of type 2 diabetes.
Fungi – A Promising Source Of Chemical Diversity
Moulds and plants share similar ways in alkaloid biosynthesis .
How Prions Kill Neurons: New Culture System Shows Early Toxicity to Dendritic Spines
Boston University researchers have developed a cell culture system to study prions.
Great Migration and African-American Genomic Diversity
Study examines genetic data to analyze regional differences in ancestry.
Faster, More Efficient CRISPR Editing
UC Berkeley scientists have developed a quicker and more efficient method to alter the genes of mice with CRISPR-Cas9, simplifying a procedure growing in popularity because of the ease of using the new gene-editing tool.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!